Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blow warned

This article was originally published in The Tan Sheet

Executive Summary

FDA challenges Iloveblow.com for marketing Blow energy drink mix as an alternative to an illicit street drug, according to a warning letter posted Feb. 26. FDA cites the product's name as well as marketing slogans and images posted on the firm's Web site, such as the name spelled out in a white granular substance, as evidence it is intended as a street drug alternative. Further, the product's marketing implies it is intended to affect the structure or function of the body, making the substance a drug, FDA says. Iloveblow.com had 15 days to respond to the warning letter, dated Jan. 31, outlining its steps to correct the cited violations. Failure to comply could lead to actions such as seizure or injunction, the agency notes. Blow's launch in 2007, like introductions of other products marketed with street drug references, immediately drew criticism from the Community Anti-Drugs Coalition of America (1"The Tan Sheet" Aug. 6, 2007, p. 10 and 2"The Tan Sheet" April 16, 2007, p. 13)...

You may also be interested in...



Blow Tests FDA’s, Industry’s Patience For Illicit Drug-Related Product Brands

Three months after FDA acted on a trade group's complaint and took enforcement action against an energy beverage firm for marketing its product as an alternative to an illicit street drug, the dietary supplement industry has another opportunity to judge how well the agency responds to a firm using drug jargon to market a product

FDA Cocaine Crackdown A “Long Overdue” Positive Development – Industry

FDA's enforcement against Redux Beverages' unlawful claims for its Cocaine energy beverage is both welcome and long overdue, the Council for Responsible Nutrition says

Pipeline Watch: Clinical Trial Starts In COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

UsernamePublicRestriction

Register

PS101405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel